Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 31.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,938 shares of the specialty pharmaceutical company's stock after selling 66,821 shares during the quarter. Principal Financial Group Inc. owned about 0.23% of Jazz Pharmaceuticals worth $15,925,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of JAZZ. Vanguard Group Inc. increased its holdings in Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company's stock worth $776,551,000 after acquiring an additional 84,941 shares in the last quarter. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock worth $264,750,000 after purchasing an additional 99,705 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock worth $194,346,000 after buying an additional 527,187 shares in the last quarter. Capital World Investors acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $171,943,000. Finally, Baupost Group LLC MA lifted its stake in shares of Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock worth $136,000,000 after buying an additional 440,552 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 2.1 %

JAZZ traded down $2.62 on Friday, reaching $121.65. 718,165 shares of the company's stock were exchanged, compared to its average volume of 678,628. The company's 50 day moving average is $112.22 and its 200-day moving average is $110.35. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market cap of $7.35 billion, a price-to-earnings ratio of 17.13, a PEG ratio of 1.07 and a beta of 0.57.

Insider Activity at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 6,110 shares of company stock worth $720,160. 4.20% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JAZZ. Piper Sandler cut their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating for the company in a research report on Thursday, August 1st. Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating for the company in a research report on Thursday, August 1st. HC Wainwright reaffirmed a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Wells Fargo & Company reduced their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $175.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.